{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:31:57Z","timestamp":1786422717684,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cca.2026.121129","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:42:44Z","timestamp":1780292564000},"page":"121129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Calreticulin mutations in essential thrombocythemia and primary myelofibrosis"],"prefix":"10.1016","volume":"591","author":[{"given":"Asif Ahmad","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Agnihotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tahir","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.cca.2026.121129_bb0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1080\/14656566.2017.1404574","article-title":"The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium","volume":"18","author":"Griesshammer","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121129_bb0015","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.clml.2011.04.002","article-title":"BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment","volume":"11","author":"Vakil","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.cca.2026.121129_bb0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cca.2026.121129_bb0030","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cca.2026.121129_bb0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3343\/alm.2015.35.1.22","article-title":"Calreticulin exon 9 mutations in myeloproliferative neoplasms","volume":"35","author":"Ha","year":"2015","journal-title":"Ann. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3343\/alm.2015.35.2.233","article-title":"Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea","volume":"35","author":"Park","year":"2015","journal-title":"Ann. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.30699\/ijp.2021.136458.2495","article-title":"JAK2, CALR, and MPL mutation profiles in BCR-ABL negative myeloproliferative neoplasms, a referral center experience in the Middle East","volume":"16","author":"Safavi","year":"2021","journal-title":"Iran. J. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jmoldx.2024.10.003","article-title":"Analysis of molecular testing for suspected myeloproliferative neoplasm at a hybrid community-academic health system","volume":"27","author":"Stone","year":"2025","journal-title":"J. Mol. Diagn."},{"issue":"12","key":"10.1016\/j.cca.2026.121129_bb0060","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ajh.24578","article-title":"Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms","volume":"91","author":"Xia","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0065","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.3390\/ijms22073371","article-title":"The contemporary approach to CALR-positive myeloproliferative neoplasms","volume":"22","author":"Bel\u010di\u010d Miki\u010d","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0070","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0080","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"issue":"33","key":"10.1016\/j.cca.2026.121129_bb0090","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.10376","article-title":"CALR mutation characterization in myeloproliferative neoplasms","volume":"7","author":"Bilbao-Sieyro","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0095","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1002\/ajh.25065","article-title":"Mayo CALR mutation type classification guide using alpha helix propensity","volume":"93","author":"Lasho","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0100","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41388-018-0538-z","article-title":"Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice","volume":"38","author":"Toppaldoddi","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.cca.2026.121129_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111689","article-title":"Calreticulin mutations affect its chaperone function and perturb the glycoproteome","volume":"41","author":"Sch\u00fcrch","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0110","doi-asserted-by":"crossref","first-page":"19838","DOI":"10.1038\/s41598-019-56236-x","article-title":"CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms","volume":"9","author":"Belcic Mikic","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0115","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/2159-8290.CD-16-0238","article-title":"Molecular mechanism of mutant CALR-mediated transformation","volume":"6","author":"Stanley","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion","volume":"9","author":"Han","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0125","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.83","article-title":"Expression of CALR mutants causes MPL-dependent thrombocytosis in zebrafish","volume":"6","author":"Lim","year":"2016","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.cca.2026.121129_bb0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2026.121129_bb0140","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.stemcr.2021.09.019","article-title":"CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes","volume":"16","author":"Olschok","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0145","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2017.178988","article-title":"JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"103","author":"Wong","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0155","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0160","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103511","article-title":"High-resolution melting analysis: a rapid and accurate method to detect CALR mutations","volume":"9","author":"Bilbao-Sieyro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121129_bb0170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cca.2014.11.011","article-title":"Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis","volume":"440","author":"Lim","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.cca.2026.121129_bb0175","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/j.clml.2021.01.017","article-title":"Clinical and molecular attributes of patients with BCR\/ABL1-negative myeloproliferative neoplasms in India: real-world data and challenges","volume":"21","author":"Singh","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.56875\/2589-0646.1064","article-title":"JAK2\/STAT5 pathway mutation frequencies in south African BCR\/ABL negative MPN patients","volume":"16","author":"Shires","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0185","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3346\/jkms.2015.30.7.882","article-title":"JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis","volume":"30","author":"Kim","year":"2015","journal-title":"J. Korean Med. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0190","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0195","article-title":"JAK2, CALR, and MPL mutation profiles in Colombian patients with BCR-ABL negative myeloproliferative neoplasms","volume":"54","author":"Giraldo-Rinc\u00f3n","year":"2023","journal-title":"Colomb. Med. (Cali)"},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/gtmb.2017.0203","article-title":"Development of a targeted next-generation sequencing assay to detect diagnostically relevant mutations of JAK2, CALR, and MPL in myeloproliferative neoplasms","volume":"22","author":"Frawley","year":"2018","journal-title":"Genet. Test. Mol. Biomarkers"},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0205","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience","volume":"2","author":"Alduaij","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.cca.2026.121129_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637116","article-title":"Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study","volume":"11","author":"Cattaneo","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.121129_bb0215","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-022-04920-w","article-title":"Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing","volume":"101","author":"Maddali","year":"2022","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0220","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","article-title":"Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome","volume":"101","author":"Asp","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0225","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ijlh.12484","article-title":"Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR","volume":"38","author":"Murugesan","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0230","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-014-2232-8","article-title":"Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring","volume":"94","author":"Chi","year":"2015","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.cca.2026.121129_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jcp-2023-208861","article-title":"High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants","volume":"77","author":"Sande","year":"2024","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13353-025-00947-7","article-title":"CALR-mutant myeloproliferative neoplasms: insights from next-generation sequencing","volume":"67","author":"Mroczkowska-B\u0119karciak","year":"2026","journal-title":"J. Appl. Genet."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmoldx.2015.07.007","article-title":"Quantification of the mutant CALR allelic burden by digital PCR: application to minimal residual disease evaluation after bone marrow transplantation","volume":"18","author":"Mansier","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121129_bb0250","article-title":"Case report: application of targeted NGS for the detection of non-canonical driver variants in MPN","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Genet."},{"issue":"15","key":"10.1016\/j.cca.2026.121129_bb0255","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0260","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","article-title":"Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms","volume":"39","author":"Jones","year":"2015","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.cca.2026.121129_bb0265","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0270","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.cca.2026.121129_bb0275","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0280","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.13561","article-title":"The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: a multicentre collaborative study","volume":"106","author":"P\u00e9rez Encinas","year":"2021","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.cca.2026.121129_bb0285","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.cca.2026.121129_bb0290","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.2023023428","article-title":"CALR mutation burden in essential thrombocythemia and disease outcome","volume":"143","author":"Guglielmelli","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cca.2026.121129_bb0295","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0300","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cca.2026.121129_bb0305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jclinpath-2017-204829","article-title":"The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis","volume":"71","author":"Kuo","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2026.121129_bb0310","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0320","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2026.121129_bb0325","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.25335","article-title":"Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0340","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0345","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0350","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.cca.2026.121129_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138250","article-title":"Frequencies, laboratory features, and granulocyte activation in Chinese patients with CALR-mutated myeloproliferative neoplasms","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0365","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.leukres.2015.02.006","article-title":"Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations","volume":"39","author":"Li","year":"2015","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/j.cca.2026.121129_bb0370","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.16797","article-title":"Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms","volume":"8","author":"Cavalloni","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.cca.2026.121129_bb0375","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.3390\/diagnostics12112570","article-title":"Effects of CALR-mutant type and burden on the phenotype of myeloproliferative neoplasms","volume":"12","author":"Kim","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0380","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/16078454.2022.2107888","article-title":"The different variant allele frequencies of type I\/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis","volume":"27","author":"Pan","year":"2022","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.cca.2026.121129_bb0385","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11845-022-03047-1","article-title":"CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients","volume":"192","author":"Weir","year":"2023","journal-title":"Ir. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0390","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ajh.27265","article-title":"CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: a study on behalf of FIM and GBMHM","volume":"99","author":"Aubin","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0395","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0400","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11899-024-00739-6","article-title":"Prognostic and predictive models in myelofibrosis","volume":"19","author":"Mora","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.27270","article-title":"Risk models in myelofibrosis: the past, present, and future","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.cca.2026.121129_bb0410","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.cca.2026.121129_bb0415","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.2025028642","article-title":"Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis","volume":"147","author":"Salzman","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121129_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1240678","article-title":"Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow","volume":"14","author":"Holmstr\u00f6m","year":"2023","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.cca.2026.121129_bb0425","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.3390\/ijerph18147582","article-title":"Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN)","volume":"18","author":"Zulkeflee","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"10.1016\/j.cca.2026.121129_bb0430","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ijlh.13938","article-title":"Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-tm method in i-densy IS-5320","volume":"44","author":"Arai","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"issue":"12","key":"10.1016\/j.cca.2026.121129_bb0435","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1038\/s41375-024-02425-1","article-title":"Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase","volume":"38","author":"Walter","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0440","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/labmed\/lmaf004","article-title":"A comparison of sequential polymerase chain reaction-based cascade testing vs next-generation sequencing in molecular profiling of myeloproliferative neoplasms: improving testing strategies in light of evolving molecular landscapes","volume":"56","author":"Liu","year":"2025","journal-title":"Lab. Med."},{"issue":"15","key":"10.1016\/j.cca.2026.121129_bb0445","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cca.2026.121129_bb0450","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00277-016-2739-2","article-title":"Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms","volume":"95","author":"Anelli","year":"2016","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.cca.2026.121129_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165336","article-title":"Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment","volume":"11","author":"Kj\u00e6r","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cca.2026.121129_bb0460","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ajcp\/aqad170","article-title":"Noncanonical CALR variants","volume":"161","author":"Langabeer","year":"2024","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2026.121129_bb0465","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.009","article-title":"Detection of CALR mutations using high-resolution melting curve analysis (HRM-A); application on a large cohort of Greek ET and MF patients","volume":"11","author":"Giannopoulos","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:18Z","timestamp":1786422078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":93,"alternative-id":["S0009898126003116"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121129","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calreticulin mutations in essential thrombocythemia and primary myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121129"}}